These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Weickhardt AJ; Rothman MS; Salian-Mehta S; Kiseljak-Vassiliades K; Oton AB; Doebele RC; Wierman ME; Camidge DR Cancer; 2012 Nov; 118(21):5302-9. PubMed ID: 22488744 [TBL] [Abstract][Full Text] [Related]
26. Crizotinib-associated erythema multiforme in a lung cancer patient. Sawamura S; Kajihara I; Ichihara A; Fukushima S; Jinnin M; Yamaguchi E; Kohrogi H; Ihn H Drug Discov Ther; 2015 Apr; 9(2):142-3. PubMed ID: 25994067 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). Di Maio M; De Marinis F; Hirsch FR; Gridelli C Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689 [TBL] [Abstract][Full Text] [Related]
28. Crizotinib in the treatment of non--small-cell lung cancer. Rothschild SI; Gautschi O Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969 [TBL] [Abstract][Full Text] [Related]
29. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942 [TBL] [Abstract][Full Text] [Related]
30. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925 [TBL] [Abstract][Full Text] [Related]
31. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559 [TBL] [Abstract][Full Text] [Related]
32. Widespread renal polycystosis induced by crizotinib. Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of crizotinib in NSCLC patients. Hamilton G; Rath B; Burghuber O Expert Opin Drug Metab Toxicol; 2015 May; 11(5):835-42. PubMed ID: 25732197 [TBL] [Abstract][Full Text] [Related]
34. [Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC]. Gao E; Zhao J; Zhuo M; Wang Z; Wang Y; An T; Wu M; Yang X; Zhong J Zhongguo Fei Ai Za Zhi; 2016 Mar; 19(3):161-8. PubMed ID: 27009821 [TBL] [Abstract][Full Text] [Related]
36. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. Srivastava N; VanderLaan PA; Kelly CP; Costa DB J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563 [No Abstract] [Full Text] [Related]